Bristol-Myers Squibb, Novartis, Merck, Alnylam Pharmaceuticals and Amgen are investing billions of dollars into a potential comeback, but it could be a costly blunder if history repeats itself, according to the Journal.
Developing heart treatments is a more difficult process than other ventures because trials require more subjects and longer timelines than others, such as cancer drugs, and heart conditions are complicated by more factors than just one organ.
“Cholesterol issues, blood pressure issues, diabetes, diet, physical activity, behavior — all these things work together in the background of your genetic predisposition,” Donald Lloyd-Jones, MD, a cardiologist and chief of preventive medicine at Northwestern University Feinberg School of Medicine in Chicago, told the Journal.
Some drugmakers are further along than others, almost acting like the industry’s own test subject after past heart therapies failed to make expected profits. If successful, the drug companies could pump the $48 billion heart drug market up to $65 billion by 2026, analysts told the Journal.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
